Ken Griffin Coherus Bio Sciences, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 215,500 shares of CHRS stock, worth $241,360. This represents 0.0% of its overall portfolio holdings.
Number of Shares
215,500
Previous 29,300
635.49%
Holding current value
$241,360
Previous $30,000
890.0%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding CHRS
# of Institutions
131Shares Held
67.8MCall Options Held
1.68MPut Options Held
91.8K-
Black Rock Inc. New York, NY11.8MShares$13.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$12.5 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.28MShares$5.92 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY5.26MShares$5.89 Million0.12% of portfolio
-
Tang Capital Management LLC San Diego, CA3.65MShares$4.09 Million0.38% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $87.1M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...